entity

GPR109A/HDAC inhibition pathway

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GPR109A/HDAC inhibition pathway: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
0Hypotheses
1Analyses
0Outgoing
1Incoming
0Experiments
1Debates

No AI portrait yet

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (1)

SourceRelationTypeStr
butyrateactivatesdrug0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.703

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

closed · Rounds: 4 · Score: 0.84 · 2026-04-16

Related Research

Hypotheses and analyses mentioning GPR109A/HDAC inhibition pathway in their description or question text

No additional research found